**Core tip:** The incidence of complications of peptic ulcer has not been decreasing and only a few data is available about epidemiological characteristics and associated risk factors of perforated peptic ulcer. In a retrospective review of medical records from multicenter in Korea revealed that elderly patients with comorbidities were associated with non-steroidal anti-inflammatory drugs (NSAIDs)-associated peptic ulcer perforation and non-*Helicobacter pylori* (*H. pylori*), non-NSAID peptic ulcer is important etiology in the development of peptic ulcer perforation. In a multivariate logistic regression analysis, alcohol consumption was suspected to be associated risk factors for the development of non-*H. pylori*, non-NSAID peptic perforation.

INTRODUCTION
============

The decreasing prevalence of *Helicobacter pylori* (*H. pylori*) infection and improvement of peptic ulcer treatment such as proton pump inhibitors (PPIs) or eradication therapies for *H. pylori* resulted in reduction of the incidence of uncomplicated peptic ulcer disease in recent decades\[[@B1]-[@B3]\]. However, several studies have shown controversial results showing constant incidence of complicated peptic ulcer disease\[[@B4]-[@B7]\], which may be due to multifactorial risk factors including the increased consumption of non-steroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA), especially in elderly patients with multiple comorbidities, smoking habits, or unknown etiologies\[[@B8],[@B9]\].

Previous studies evaluated the epidemiologic characteristics and associated risk factors of perforated peptic ulcer (PPU) and demonstrated increasing incidence of PPU by age\[[@B7]-[@B15]\]. However, these studies used national registry database rather than those from hospitals, which have potential for underestimation of true incidence or misinterpretation of characteristics of PPU. Also, *H. pylori* infection status in patients with PPU was rarely evaluated except 1 study, which included suboptimal number of subjects at early 2000s\[[@B12]\]. Also, the effect of NSAIDs or ASA on PPU was inconsistent according to the studies\[[@B5],[@B13],[@B16]\]. Therefore, this study aimed to investigate the epidemiological characteristics and associated risk factors of benign PPU using multicenter clinical data.

MATERIALS AND METHODS
=====================

Study population
----------------

We retrospectively reviewed the medical records of 402 patients who were diagnosed with PPU (either gastric or duodenal ulcer) from January 2010 through December 2015 at Hallym university-affiliated hospitals, including the Chuncheon, Kangdong, Dongtan, Hangang, Kangnam and Hallym University Sacred Heart Hospital. Except 6 patients with unknown histology of PPU, remaining 396 ulcers were verified as benign ulcers by histology after surgical resection or endoscopic biopsy. This study was approved by the institutional review board of Chuncheon Sacred Heart Hospital (2016-86).

Data collection
---------------

We retrospectively collected the clinical data including age, sex, body mass index (BMI), smoking status and alcohol consumption for the last 3 mo, presence of any comorbidities, and current medications, such as NSAIDs or ASA, steroid, H~2~-blockers, or PPIs. BMI was calculated as weight in kilograms divided by the square of height in meters. Positive alcohol consumption was defined as those who drink more than 20 g of alcohol amount in a week.

Chief complaints and laboratory data including white blood count (WBC), hemoglobin (Hb), serum creatinine (~S~Cr), C-reactive protein (CRP) at admission period were obtained. Also, sites of perforation, treatment methods, the development of postoperative complication if surgical management was done, the length of hospital stay, and mortality rate were identified. The sites of perforation were divided into 3 areas in stomach (from cardiac to body area, proximal antrum, and from prepyloric to pyloric area) and 2 areas in duodenum (bulb, and 2^nd^ portion). The size of perforated peptic ulcer was categorized on the basis of centimeter. The methods of operation were classified into 3 groups: (1) simple closure with or without omentopexy; (2) pyloroplasty with or without vagotomy; and (3) any other form of gastrectomy (total, subtotal, or antrectomy). If patients were assessed *H. pylori* infection status, diagnostic methods such as rapid urease test, ^13^C-urea breath test, or the serological test and the infection status were identified. All patients who were examined for *H. pylori* were discontinued PPIs or H~2~-blockers at least 4 wk before *H. pylori* test. Treatment regimen and whether the treatment was successful or not were also identified.

Statistical analysis
--------------------

Continuous variables were expressed as mean ± SD. Categorical variables were expressed as number and percentage. We compared the differences in the clinical characteristics and therapeutic outcomes of the study population using the Student's *t*-test for the continuous variables and the Fisher's exact test for the categorical variables. To identify the risk of non-*H. pylori*, non-NSAIDs associate PPU, we performed univariate and subsequent multivariate logistic regression analysis. In this study, a *P* value \< 0.05 (2-tailed) was adopted as the threshold of statistical significance for all tests. All of the analyses were performed using SPSS version 20.0. (SPSS Inc., Chicago, IL, United States).

RESULTS
=======

Baseline characteristics of enrolled populations
------------------------------------------------

The baseline characteristics of the study population and site specific characteristics classified according to the site of perforation are shown in Table [1](#T1){ref-type="table"}. We identified a total of 396 benign PPU patients, consisting of 173 (43.7%) in gastric ulcer group and 223 (56.3%) in duodenal ulcer group. Men predominance was observed (85.1%). The mean age and BMI of the subjects were 50.6 ± 18.3 years and 21.7 ± 2.9 kg/m^2^, respectively. And about half of patients had alcohol consumption (47.2%) and smoking habit (55.8%). Of all, 54 (13.6%) patients had been diagnosed with peptic ulcer at median 12 mo before the time of perforation (interquartile range: 2-36 mo). In terms of the comorbidities, 123 (31.1%) patients had at least one comorbidities, which were cardiovascular disease (67.5%), diabetes mellitus (33.3%), chronic liver disease (10.6%) and cerebrovascular disease (8.9%) in the order. The proportion of taking medication was as follows; 44 (11.2%) patients on NSAIDs including ASA (*n* = 23), 8 (2%) patients on steroid, and 31 (7.8%) patents on anti-ulcer medication such as PPIs (*n* = 19) or H~2~-blocker (*n* = 12).

###### 

Baseline characteristics of enrolled population *n* (%)

  **Variables**                              **Total**       **Gastric ulcer**   **Duodenal ulcer**   ***P* value**
  ------------------------------------------ --------------- ------------------- -------------------- ---------------
  Sex (men)                                  337 (85.1)      145 (83.8)          192 (86.1)           0.57
  Age                                        50.6 ± 18.3     51.4 ± 19.0         50.1 ± 17.8          0.49
  BMI (kg/m^2^)                              21.7 ± 2.9      21.5 ± 2.9          21.9 ± 3.0           0.14
  Alcohol consumption                        187 (47.2)      76 (43.9)           111 (49.8)           0.27
  Current smoking                            221 (55.8)      98 (56.6)           123 (55.2)           0.84
  Previous ulcer history                     54 (13.6)       27 (15.6)           27 (12.1)            0.38
  Comorbidity                                123 (31.1)      61 (35.3)           62 (27.8)            0.13
  Cardiovascular disease                     83 (67.5)       38 (62.3)           45 (72.6)            0.22
  DM                                         41 (33.3)       18 (29.5)           23 (37.1)            0.45
  Chronic liver disease                      13 (10.6)       8 (13.1)            5 (8.1)              0.40
  Cerebrovascular disease                    11 (8.9)        4 (6.6)             7 (11.3)             0.36
  Malignancy                                 9 (7.3)         6 (9.8)             3 (4.8)              0.24
  Chronic kidney injury                      6 (4.9)         4 (6.6)             2 (3.2)              0.33
  Pulmonary disease                          4 (3.3)         3 (4.9)             1 (1.6)              0.30
  Infectious disease                         3 (2.4)         2 (3.3)             1 (1.6)              0.49
  Current medication                                                                                  
  NSAIDs                                     44 (11.2)       20 (11.7)           24 (10.8)            0.87
  Steroid                                    8 (2.0)         5 (2.9)             3 (1.3)              0.23
  Proton pump inhibitor                      19 (4.8)        11 (6.4)            8 (3.6)              0.24
  H~2~-blocker                               12 (3.0)        5 (2.9)             7 (3.1)              \> 0.99
  Presentation                                                                                        0.39
  Abdominal pain                             365 (92.2)      155 (89.6)          210 (94.2)           
  Melena/hematemesis                         16 (4.0)        9 (5.2)             7 (3.1)              
  Shock                                      5 (1.3)         2 (1.2)             3 (1.3)              
  Epigastric soreness                        6 (1.5)         4 (2.3)             2 (0.9)              
  Nausea/vomiting                            4 (1.0)         3 (1.7)             1 (0.4)              
  Laboratory findings                                                                                 
  White blood count (x10^3^/uL)              13.4 ± 7.8      12.9 ± 5.3          13.8 ± 9.4           0.24
  Hemoglobin (g/dL)                          13.7 ± 6.0      13.7 ± 8.8          13.7 ± 2.2           0.95
  Serum Creatinine (mg/dL)                   1.02 ± 0.7      1.01 ± 0.7          1.03 ± 0.6           0.87
  C-reactive protein (mg/L)                  93.7 ± 89.0     88.9 ± 86.0         97.2 ± 91.1          0.39
  Anatomical findings                                                                                 
  Location                                                                                            
  Stomach                                    173 (43.7)                                               
  Body                                                       11 (6.4)                                 
  Antrum                                                     62 (35.8)                                
  Pylorus                                                    100 (57.8)                               
  Duodenum                                   223 (56.3)                                               
  Bulb                                                                           218 (97.8)           
  2^nd^ portion                                                                  5 (2.2)              
  Size                                                                                                0.82
  ≥ 1 cm                                     126 (37.6)      58 (38.4)           68 (37.0)            
  \< 1 cm                                    209 (62.4)      93 (61.6)           116 (63.0)           
  *H. pylori* test                                                                                    
  Positivity *H. pylori* test                78/174 (44.8)   30/72 (41.7)        48/102 (47.1)        0.48
  Rapid urease test                          60 (76.9)       26 (86.7)           34 (70.8)            
  Urea breath test                           5 (6.4)         2 (6.7)             3 (6.2)              
  Serology test                              13 (16.7)       2 (6.7)             11 (22.9)            
  Operation                                  388 (98.0)      170 (98.3)          218 (97.8)           0.51
  Primary closure and/or omentopexy          307 (79.5)      139 (81.7)          168 (77.8)           
  Pyloroplasty and/or vagotomy               43 (11.1)       15 (8.8)            28 (13.0)            
  Total/subtotal gastrectomy or antrectomy   36 (9.3)        16 (9.5)            20 (9.2)             
  Others (Whipple's operation, drainage)     2 (0.5)         0 (0.0)             2 (0.9)              
  Medical treatment                          8 (2.0)         3 (1.7)             5 (2.2)              0.09
  Clinical course                                                                                     
  Hospital stay                              13.1 ± 9.4      13.4 ± 10.4         12.8 ± 8.7           0.54
  Complication                               36 (9.1)        21 (12.1)           15 (6.7)             0.08
  In hospital mortality                      3 (0.8)         2 (1.2)             1 (0.4)              0.58

PPU: Perforated peptic ulcer; BMI: Body mass index; DM: Diabetes mellitus; NSAIDs: Non-steroidal anti-inflammatory drugs; *H. pylori*: *Helicobacter pylori*.

At admission, the majority of patients (92.2%) complained abdominal pain and 16 (4.0%) patients experienced melena or hematemesis. The mean levels of WBC (13.4 ± 7.8 × 10^3^/uL) and CRP (93.7 ± 89.0 mg/L) were above normal range. However, the mean levels of Hb (13.7 ± 6.0 g/dL) and ~S~Cr (1.02 ± 0.7 mg/dL) were within normal value. Among 174 (43.9%) patients who were tested for *H. pylori* infection, 78 (44.8%) patients were positive for *H. pylori* tests, which were rapid urease test (*n* = 60), urea breath test (*n* = 5), and serologic test (*n* = 13). Comparing with the 222 patients who did not perform *H. pylori* test, patients who tested for *H. pylori* infection were significantly younger (47.6 ± 16.8 *vs* 53.0 ± 19.1 years, *P* = 0.003) and none of them had malignant disease. The other baseline characteristics were comparable between the patients who were tested for *H. pylori* infection or not (Table [2](#T2){ref-type="table"}). Except 9 patients who were lost to follow-up, 69 (88.5%) patients were prescribed with 7 or 14 d of standard triple therapy (*n* = 66), or 14 d of bismuth-based quadruple therapy (*n* = 3) as the first-line regimen. Among them, 33 patients achieved successful eradication after the first-line treatment (eradication rate of 47.8%) and 4 patients who failed to eradication after first line regimen achieved successful eradication after 2^nd^ line treatment (overall eradication rate of 53.6%). We could not evaluate eradication status in the remaining 32 patients due to lost to follow up during or after eradication treatment.

###### 

Comparison of clinical characteristics between patients with perforated peptic ulcer who were tested for *Helicobacter pylori* infection or not *n* (%)

  **Variables**                          **Total (*n* = 396)**   **Gastric ulcer (*n* = 173)**   **Duodenal ulcer (*n* = 223)**                                                                    
  -------------------------------------- ----------------------- ------------------------------- -------------------------------- ------------- ------------ --------- ------------- ------------- ---------
  Sex (men)                              151 (86.8)              186 (83.8)                      0.480                            60 (83.3)     85 (84.2)    \> 0.99   91 (89.2)     101 (83.5)    0.25
  Age (yr)                               47.6 ± 16.8             53.0 ± 19.1                     0.003                            47.5 ± 18.3   54.1± 19.1   0.02      47.6 ± 15.7   52.2 ± 19.1   0.05
  \< 60                                  133 (76.4)              142 (64.0)                      0.008                            56 (77.8)     61 (60.4)    0.02      77 (75.5)     81 (66.9)     0.18
  ≥ 60                                   41 (23.6)               80 (36.0)                                                        16 (22.2)     40 (39.6)              25 (24.5)     40 (33.1)     
  BMI (kg/m^2^)                          22.0 ± 3.1              21.5 ± 2.8                      0.150                            21.5 ± 3.1    21.4 ± 2.7   0.83      22.3 ± 3.0    21.6 ± 3.00   0.10
  Alcohol drinking                       87 (50.0)               100 (45.0)                      0.360                            33 (45.8)     43 (42.6)    0.76      54 (52.9)     57 (47.1)     0.42
  Current smoking                        97 (55.7)               124 (55.9)                      \> 0.99                          39 (54.2)     59 (58.4)    0.64      58 (56.9)     65 (53.7)     0.69
  Both alcohol consumption and smoking   69 (39.7)               85 (38.3)                       0.840                            24 (33.3)     36 (35.6)    0.87      45 (44.1)     49 (40.5)     0.59
  Previous ulcer history                 30 (17.2)               24 (10.8)                       0.08                             14 (19.4)     13 (12.9)    0.29      16 (15.7)     11 (9.1)      0.15
  Comorbidity                            44 (25.3)               79 (35.6)                       0.03                             21 (29.2)     40 (39.6)    0.2       23 (22.5)     39 (32.2)     0.13
  HTN                                    27 (61.4)               55 (69.6)                       0.43                             14 (66.7)     24 (60.0)    0.78      13 (56.5)     31 (79.5)     0.08
  DM                                     13 (29.5)               28 (35.4)                       0.55                             5 (23.8)      13 (32.5)    0.56      8 (34.8)      15 (38.5)     \> 0.99
  Cardiovascular disease                 6 (13.6)                15 (19.0)                       0.62                             3 (14.3)      7 (17.5)     0.53      3 (13.0)      8 (20.5)      0.35
  Chronic liver disease                  5 (11.4)                8 (10.1)                        0.53                             1 (4.8)       7 (17.5)     0.24      4 (17.4)      1 (2.6)       0.06
  Malignancy                             0 (0.0)                 9 (11.4)                        0.02                             0 (0.0)       6 (15.0)     0.07      0 (0.0)       3 (7.7)       0.24
  Chronic kidney injury                  3 (6.8)                 3 (3.8)                         0.17                             2 (9.5)       2 (5.0)      0.43      1 (4.3)       1 (2.6)       0.61
  Pulmonary disease                      0 (0.0)                 4 (5.1)                         0.37                             0 (0.0)       3 (7.5)      0.28      0 (0.0)       1 (2.6)       0.63
  Infectious disease                     1 (2.3)                 2 (2.5)                         0.71                             1 (4.8)       1 (2.5)      0.57      0 (0.0)       1 (2.6)       0.63
  Current medication                                                                                                                                                                               
  NSAIDs                                 21 (12.1)               23 (10.4)                       0.63                             9 (12.7)      11 (11.0)    0.81      12 (11.8)     12 (9.9)      0.67
  Steroid                                2 (1.2)                 6 (2.7)                         0.24                             1 (1.4)       4 (4.0)      0.31      1 (1.0)       2 (1.7)       0.56
  Proton pump inhibitor                  7 (4.0)                 12 (5.4)                        0.64                             3 (4.2)       8 (7.9)      0.26      4 (3.9)       4 (3.3)       0.54
  H~2~-blocker                           4 (2.3)                 8 (3.6)                         0.56                             3 (4.2)       2 (2.0)      0.34      1 (1.0)       6 (5.0)       0.09

PPU: Perforated peptic ulcer; BMI: Body mass index; HTN: Hypertension; DM: Diabetes mellitus; NSAIDs: Non-steroidal anti-inflammatory drugs; *H. pylori*: *Helicobacter pylori*.

In terms of the site of perforation, bulb of duodenum (55.1%) was the most common site, followed by pylorus (25.3%), and antrum (15.7%). The proportion of duodenal ulcer perforation was 56.3% and the gastric ulcer perforation was 43.7%, respectively. Except 8 (2.0%) patients who were treated by medical management, remaining 388 patients (98.0%) underwent surgical management. The operative methods were primary closure with or without omentopexy (*n* = 307), pyloroplasty with or without vagotomy (*n* = 43), and any other form of gastrectomy (total, subtotal or antrectomy, *n* = 36). The mean duration of hospital stay was 13.1 ± 9.4 d. Though 36 (9.1%) patients experienced postoperative complication, only 3 (0.8%) patients died during hospitalization because of acute respiratory distress syndrome or uncontrolled sepsis. All of the baseline characteristics and clinical manifestations were comparable between perforated gastric ulcer and duodenal ulcer group. The detailed characteristics of all of the enrolled population are described in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

The annual incidences of PPU showed decreasing trend for study periods, especially in gastric ulcer (Figure [1](#F1){ref-type="fig"}). The incidence of gastric ulcer perforation was 49.8% in the first 3 years and 36.9% in the last 3 years, which was statistically significant (*P* = 0.01). The decreasing incidence of perforated gastric ulcer was mainly observed in male under the age of 60. In these patients, the proportions of *H. pylori* infection, NSAIDs use, alcohol consumption, and any comorbidities were increased during study period, whereas the proportion of smoking habit was decreased from 65.9% in the first 3 years to 57.9% in the last 3 years, although the statistical significance was not reached.

![Annual incidence of perforated peptic ulcer according to anatomic location.](WJG-23-2566-g001){#F1}

Comparison of clinical characteristics and manifestations according to age
--------------------------------------------------------------------------

Among 396 patients, 121 (30.6%) patients were older than 60 years and the proportion of women was significantly higher in patients older than 60 years (old age group) compared with patients younger than 60 years (young age group) (5.5% *vs* 36.4%, *P* \< 0.001). The proportion of alcohol consumption (56.0% *vs* 27.3%) and smoking habit (62.5% *vs* 40.5%) was higher in young age group than those of patients in old age group (*P* \< 0.001). The proportions of patients with comorbidities (14.9% *vs* 67.8%) and taking NSAIDs (2.9% *vs* 30.0%) were significantly higher in old age group (*P* \< 0.001), whereas the proportion of patients with *H. pylori* infection was significantly higher in young age group (50.4% *vs* 26.8%, *P* = 0.008). Although the site of perforation was comparable between two groups, the higher proportion of patients in old age group had PPU over 1 cm (31.1% *vs* 53.0%, *P* \< 0.001). Moreover, the length of hospitalization (11.3 ± 7.7 *vs* 17.0 ± 11.7 d) and postoperative complication rate (4.0% *vs* 20.7%) were significantly higher in old age group (*P* \< 0.001). All of the in-hospital mortality cases were also occurred in old age group (Table [3](#T3){ref-type="table"}).

###### 

Comparison of clinical characteristics of perforated peptic ulcer according to age *n* (%)

  **Variables**                 **\< 60 yr**    ≥ **60 yr**    ***P* value**
  ----------------------------- --------------- -------------- ---------------
  Sex (men)                     260 (94.5)      77 (63.6)      \< 0.001
  BMI (kg/m^2^)                 21.8 ± 2.7      21.5 ± 3.4     0.33
  Alcohol consumption           154 (56.0)      33 (27.3)      \< 0.001
  Current smoking               172 (62.5)      49 (40.5)      \< 0.001
  Previous ulcer history        31 (11.3)       23 (19.0)      0.04
  Comorbidity                   41 (14.9)       82 (67.8)      \< 0.001
  Current medication                                           
  NSAIDs                        8 (2.9)         36 (30.0)      \< 0.001
  Steroid                       4 (1.5)         4 (3.3)        0.26
  Proton pump inhibitor         9 (3.3)         10 (8.3)       0.04
  H~2~-blocker                  5 (1.8)         7 (5.8)        0.05
  *H. pylori* test                                             
  Positivity *H. pylori* test   67/133 (50.4)   11/41 (26.8)   0.008
  Rapid urease test             52 (77.6)       8 (72.7)       
  Urea breath test              4 (6.0)         1 (9.1)        
  Serology test                 11 (16.8)       2 (18.2)       
  Anatomical findings                                          
  Location                                                     0.490
  Gastric ulcer                 117 (42.5)      56 (46.3)      
  Duodenal ulcer                158 (57.5)      65 (53.7)      
  Size                                                         \< 0.001
  ≥ 1 cm                        73 (31.1)       53 (53.0)      
  \< 1 cm                       162 (68.9)      47 (47.0)      
  Clinical course                                              
  Hospital stay                 11.3 ± 7.7      17.0 ± 11.7    \< 0.001
  Complication                  11 (4.0)        25 (20.7)      \< 0.001
  In hospital mortality         0 (0.0)         3 (2.5)        0.009

PPU: Perforated peptic ulcer; BMI: Body mass index; NSAIDs: Non-steroidal anti-inflammatory drugs; *H. pylori*: *Helicobacter pylori*.

Comparison of clinical characteristics of PPU according to the etiology
-----------------------------------------------------------------------

A total of 174 patients who were tested for *H. pylori* infection status were categorized into 4 groups in terms of the etiology of peptic ulcer (both *H. pylori* positive and NSAIDs use, either *H. pylori* positive or NSAID use, and Non-*H. pylori*, non-NSAIDs group). The patients with solely *H. pylori* positive were 73 and the patients taking NSAIDs without *H. pylori* infection were 16. Five patients were infected *H. pylori* and also taking NSAIDs (Both *H. pylori* positive and NAIDs user group). The remaining 80 patients who were negative for *H. pylori* test and not taking any kinds of NSAIDs or ASA were categorized into Non-*H. pylori*, non-NSAIDs group. Men predominance was observed consistently in all of the 4 groups. The mean age (69.5 ± 12.2 years) and the proportion of patients with any comorbidities (75.0%) were significantly higher in NSAIDs user group (*P* \< 0.001). The mean BMI level and the proportion of patients with alcohol consumption, current smoking, and peptic ulcer history were similar among the 4 groups. More than half of patients in each group experienced duodenal ulcer perforation, which were most commonly in bulb area. Also, the proportion of patients with perforation more than 1 cm in diameter was significantly higher in NSAIDs group (66.7%) than the other groups (*P* = 0.002). The lengths of hospital stay and postoperative complication rates were comparable among 4 group. There was no mortality during hospitalization in 4 groups. The detailed clinical characteristics of PPU according to the etiology are described in Table [4](#T4){ref-type="table"}.

###### 

Comparison of clinical characteristics of perforated peptic ulcer categorized by the *Helicobacter pylori*-infected, non-steroidal anti-inflammatory drugs user, and non-*Helicobacter pylori*, non-non-steroidal anti-inflammatory drugs group *n* (%)

  **Variables**            **Both *H. pylori* positive and NSAIDs user group (*n* = 5)**   ***H. pylori* positive group (*n* = 73)**   **NSAIDs user group (*n* = 16)**   **Non-*H. pylori*, Non-NSAIDs group (*n* = 80)**   ***P* value**
  ------------------------ --------------------------------------------------------------- ------------------------------------------- ---------------------------------- -------------------------------------------------- ---------------
  Sex (men)                4 (80.0)                                                        67 (91.8)                                   9 (56.2)                           71 (88.8)                                          0.005
  Age                      57.6 ± 16.0                                                     40.3 ± 15.2                                 69.5 ± 12.2                        49.1 ± 14.6                                        \< 0.001
  BMI (kg/m^2^)            24.7 ± 4.1                                                      21.6 ± 3.0                                  21.2 ± 4.3                         22.2 ± 2.8                                         0.090
  Alcohol consumption      3 (60.0)                                                        33 (45.2)                                   4 (25.0)                           47 (58.8)                                          0.060
  Current smoking          3 (60.0)                                                        36 (49.3)                                   6 (37.5)                           52 (65.0)                                          0.090
  Previous ulcer history   0 (0.0)                                                         9 (12.3)                                    4 (25.0)                           17 (21.2)                                          0.290
  Comorbidity              2 (40.0)                                                        11 (15.1)                                   12 (75.0)                          19 (23.8)                                          \< 0.001
  Anatomical findings                                                                                                                                                                                                        
  Location                                                                                                                                                                                                                   0.710
  Gastric ulcer            1 (20.0)                                                        29 (39.7)                                   8 (50.0)                           34 (42.5)                                          
  Duodenal ulcer           4 (80.0)                                                        44 (60.3)                                   8 (50.0)                           46 (57.5)                                          
  Size                                                                                                                                                                                                                       0.002
  ≥ 1 cm                   3 (60.0)                                                        15 (23.8)                                   8 (66.7)                           33 (48.5)                                          
  \< 1 cm                  2 (40.0)                                                        48 (76.2)                                   4 (33.3)                           35 (51.5)                                          
  Clinical course                                                                                                                                                                                                            
  Hospital stay            10.6 ± 4.2                                                      10.3 ± 4.5                                  12.8 ± 4.8                         13.2 ± 9.9                                         0.120
  Complication             0 (0.0)                                                         1 (1.4)                                     1 (6.2)                            6 (7.5)                                            0.240
  In hospital mortality    0 (0.0)                                                         0 (0.0)                                     0 (0.0)                            0 (0.0)                                            

PPU: Perforated peptic ulcer; BMI: Body mass index; NSAIDs: Non-steroidal anti-inflammatory drugs; *H. pylori*: *Helicobacter pylori*.

Associated risk factor of PPU according to the etiology
-------------------------------------------------------

To identify the associated risk factors according to the etiology, we performed univariate and subsequent multivariate regression analysis. Older age \[odds ratio (OR) = 1.09, 95% confidence interval (CI): 1.04-1.16\] and comorbidity (OR = 4.11, 95%CI: 1.03-16.48) were associated with NSAID-associated PPU compared with non-*H. pylori*, non-NSAID associated PPU (Table [5](#T5){ref-type="table"}). Older age (OR = 1.04, 95%CI: 1.02-1.07) and alcohol consumption (OR = 2.08, 95%CI: 1.05-4.13) were associated with non-*H. pylori*, non-NSAID associated PPU compared with solely *H. pylori* positive PPU (Table [6](#T6){ref-type="table"}).

###### 

Multivariate analysis for the risk factors of non-steroidal anti-inflammatory drugs-associated perforated peptic ulcer compared with ​non-*Helicobacter pylori*, non-non-steroidal anti-inflammatory drug associated perforated peptic ulcer

  **Variables**            **Unadjusted OR (95%CI)**   ***P* value**   **Adjusted OR (95%CI)**   ***P* value**
  ------------------------ --------------------------- --------------- ------------------------- ---------------
  Sex (men)                0.16 (0.05-0.55)            0.003                                     
  Age                      1.12 (1.06-1.17)            \< 0.001        1.09 (1.04-1.16)          0.001
  BMI (kg/m^2^)            0.89 (0.74-1.07)            0.210                                     
  Alcohol consumption      0.23 (0.07-0.79)            0.020                                     
  Current smoking          0.32 (0.11-0.98)            0.050                                     
  Previous ulcer history   1.24 (0.35-4.32)            0.740                                     
  Comorbidity              9.63 (2.78-33.39)           \< 0.001        4.11 (1.03-16.48)         0.050

All variables with *P* ≤ 0.2 by univariate analysis were analyzed by multivariate analysis. BMI: Body mass index.

###### 

Multivariate analysis for the risk factors of non-*Helicobacter pylori*, non-non-steroidal anti-inflammatory drugs perforated peptic ulcer compared with solely *Helicobacter pylori* positive perforated peptic ulcer

  **Variables**            **Unadjusted OR (95%CI)**   ***P* value**   **Adjusted OR (95%CI)**   ***P* value**
  ------------------------ --------------------------- --------------- ------------------------- ---------------
  Sex (men)                0.71 (0.24-2.09)            0.530                                     
  Age                      1.04 (1.02-1.07)            0.001           1.04 (1.02-1.07)          \< 0.001
  BMI (kg/m^2^)            1.09 (0.97-1.22)            0.160                                     
  Alcohol consumption      1.73 (0.91-3.28)            0.100           2.08 (1.05-4.13)          0.040
  Current smoking          1.91 (1.00-3.66)            0.050                                     
  Previous ulcer history   1.92 (0.80-4.63)            0.150                                     
  Comorbidity              1.76 (0.77-4.00)            0.180                                     

All variables with *P* ≤ 0.2 by univariate analysis were analyzed by multivariate analysis. BMI: Body mass index.

DISCUSSION
==========

This study evaluated the clinical characteristics of PPU and assessed the associated risk factors of PPU in terms of the common etiology. Previous western studies which evaluated the incidence and changing pattern of PPU consistently revealed that most patients with PPU were aged over 60 years without gender difference and the incidence of PPU showed increasing trend by age\[[@B3],[@B9],[@B11]\]. On the other hand, a retrospective study from Middle Eastern showed that the mean age of the patients with PPU was 35.5 years and 98.3% of patients were men\[[@B13]\]. Also, Korean population based study using national Health Insurance claims database reported that most patients with PPU were younger than 60 years with men predominance, and increasing incidence of PPU with age, especially in women\[[@B8]\], which was in agreement with our study. Due to the inherent limitation of retrospective manner of this study, selection bias could be the reason of different epidemiologic characteristics. Also, there are different pattern of risk factors (*H. pylori* infection rate, NSAIDs consumption) according to the geographical area of each study. However, our study clearly categorized 4 patterns of PPU according to the etiology of peptic ulcer and each of these groups showed distinguishing characteristics of PPU.

*H. pylori* infected group was younger than the other groups. However, this was not due to the increased prevalence of *H. pylori* infection in younger patients. As a result of the decreasing pattern of *H. pylori* infection rate and increasing pattern of NSAIDs consumption due to the elderly society in the world as well as in Korea, NSAIDs user group was relatively older than the other groups. Korean epidemiologic studies also demonstrated the increasing age of peptic ulcer occurrence in the recent decades\[[@B17]-[@B19]\].

In NSAIDs users, the size of the PPU was larger than other groups and hospital stay was relatively longer than *H. pylori* infected group, although statistically insignificant. The reason of relatively larger size PPU in the NSAIDs users could not be elucidated in this study. However, considering the direct cytotoxicity in the gastric mucosa of NSAIDs other than inhibition of prostaglandin synthesis or inflammatory responses in the development of peptic ulcer, there could be a possibility of more serious injury from NSAID in the development of PPU\[[@B20]\].

NSAIDs users were relatively older and the proportion of women was higher than the other groups, just like the characteristics of peptic ulcer in Korea\[[@B17]\]. They had also more comorbidities than other groups. However, in contrast to the higher mortality rate and silent ulcer rate without significant symptoms reported in patients with NSAID induced peptic ulcer, there was no statistically significant mortality difference in NSAID induced PPU and initial symptomatic presentation was not different from those of the others\[[@B17],[@B21]\].

*H. pylori* infection and NSAIDs consumption are still important risk factors for the development of PPU. Several studies have investigated the risk factors for the development of PPU. Gisbert et al\[[@B12]\] who compared the prevalence of *H. pylori* infection and NSAIDs treatment between PPU and uncomplicated peptic ulcer disease identified that *H. pylori* prevalence were significantly lower in PPU and NSAIDs treatment was associated with PPU in a multivariate analysis. Another study from Swedish population\[[@B5]\] suggested that NSAIDs had little influence on peptic ulcer complications reflecting declining incidences of peptic ulcer complication despite rising NSAIDs prescription after PPI introduction. However, these studies used suboptimal number of subjects with PPU or evaluated the effect of only NSAIDs on ulcer complication without consideration for *H. pylori* infection. Therefore, to the best of our knowledge, this is the first study which investigated the prevalence of not only patients with *H. pylori* infection and NSAIDs treatment but also with non-*H. pylori*, non-NSAIDs and included largest number of PPU patents using clinical data from hospitals.

Previous epidemiology study of peptic ulcer disease in Korea showed that there was substantial proportion of patients (40.6%) in non-*H. pylori*, non-NSAIDs peptic ulcer disease among peptic ulcers developed in a single tertiary center for a year\[[@B19]\], which was closely correlated with our study. In our study, almost half of the subjects (46%) were not associated with *H. pylori* infection and NSAIDs treatment and these patients had intermediate demographic characteristics between *H. pylori* infected group and NSAIDs treated group in terms of age and gender. Although the reported prevalence of non-*H. pylori*, non-NSAIDs is variable according to the geographical area due to the difference of *H. pylori* infection prevalence, previous Korean studies reported 16.2% to 22.2% of prevalence\[[@B22],[@B23]\]. This rate was intensified in the development of PPU in our study, reflecting decreasing prevalence of *H. pylori* infection in Korea.

Older age and alcohol consumption were significant risk factors of non-*H. pylori*, non-NSAIDs associated PPU compared with solely *H. pylori* positive PPU, which suggested the possible effect of aging or alcohol consumption on the development of non-*H. pylori*, non-NSAIDs associated PPU. There has been few studies about the association between aging or alcohol consumption and complicated peptic ulcer disease. Andersen et al\[[@B15]\] reported that alcohol consumption was correlated with peptic ulcer bleeding, and Charpignon et al\[[@B24]\] and Xia et al\[[@B25]\] commonly showed that aging was significant risk factor for idiopathic peptic ulcers, which might be due to the association with increased comorbidities according to aging. Also, animal study suggested that decreased defense mechanism of aging such as decreased secretion of mucus, bicarbonate or prostaglandin could be the reason of peptic ulcer in elderly patients\[[@B26]\]. To confirm the effect of aging or alcohol consumption on PPU, further studies with large population are needed.

This study had several limitations that should be addressed. First, retrospective study design had inherently hidden bias from imperfect recall and undetectable variables. Because most patients performed only one diagnostic method to evaluate *H. pylori* status and took *H. pylori* test after the management of PPU such as antibiotics use and surgical treatment, there was possibility of false-negative results of *H. pylori* test. Also, surreptitious NSAIDs/ASA use might be underestimated the proportion of NSAIDs user group. Second, we could not verify the independent risk factors of perforated peptic ulcers by comparison between the patients with PPU and patients with uncomplicated peptic ulcer disease due to rare incidence of PPU compared with uncomplicated peptic ulcers. Third, although baseline characteristics between the patients who were tested or not for the *H. pylori* infection were comparable except age, half of the patients with PPU were not evaluated for *H. pylori* infection status because of lost to follow-up after discharge, which could affect as a selection bias. Fourth, because we initially identified the patients with PPU using ICD code and then review the medical records, there was a possibility of underestimation of mortality of PPU. Although the pitfalls stated above, this study included largest population of PPU not only patients with *H. pylori* infection and NSAIDs treatment but also with non-*H. pylori*, non-NSAIDs.

In conclusion, Elderly patients with comorbidities are associated with NSAIDs-associated PPU. Non-*H. pylori*, non-NSAID peptic ulcer is important etiology in the development of PPU and alcohol consumption is associated risk factor.
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